Marker Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
899
across all filing types
Latest filing
2016-12-14
Director's Dealing
Country
US
United States of America
Listing
US
MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| OWNERSHIP DOCUMENT | 2016-12-14 | English | |
| PRIMARY DOCUMENT | 2016-11-30 | English | |
| PRIMARY DOCUMENT | 2016-11-30 | English | |
| 8-K | 2016-11-30 | English | |
| Regulatory Filings 2016 | 2016-11-15 | English | |
| AUTO-GENERATED PAPER DOCUMENT | 2016-11-07 | English |
Browse filings by year
28 years- 2026 6 filings
- 2025 47 filings
- 2024 29 filings
- 2023 40 filings
- 2022 45 filings
- 2021 67 filings
- 2020 37 filings
- 2019 43 filings
- 2018 75 filings
- 2017 45 filings
- 2016 51 filings
- 2015 58 filings
- 2014 26 filings
- 2013 15 filings
- 2012 19 filings
- 2011 39 filings
- 2010 31 filings
- 2009 22 filings
- 2008 18 filings
- 2007 22 filings
- 2006 10 filings
- 2005 16 filings
- 2004 33 filings
- 2003 15 filings
- 2002 56 filings
- 2001 21 filings
- 2000 10 filings
- 1999 3 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2016
15 filings
| |||||
| 11219356 | OWNERSHIP DOCUMENT | 2016-12-14 | English | ||
| 11219357 | PRIMARY DOCUMENT | 2016-11-30 | English | ||
| 11219358 | PRIMARY DOCUMENT | 2016-11-30 | English | ||
| 11219359 | 8-K | 2016-11-30 | English | ||
| 11219360 | Regulatory Filings 2016 | 2016-11-15 | English | ||
| 11219361 | AUTO-GENERATED PAPER DOCUMENT | 2016-11-07 | English | ||
| 11219362 | PROSPECTUS SUPPLEMENT NO. 3 | 2016-11-07 | English | ||
| 11219367 | 10-Q | 2016-11-04 | English | ||
| 11219368 | 8-A12B | 2016-11-03 | English | ||
| 11219369 | PROSPECTUS SUPPLEMENT NO. 2 | 2016-09-15 | English | ||
| 11219370 | FORM 8-K | 2016-09-15 | English | ||
| 11219371 | Regulatory Filings 2016 | 2016-09-09 | English | ||
| 11219372 | FORM 8-K | 2016-08-29 | English | ||
| 11219373 | FORM 4 SUBMISSION | 2016-08-25 | English | ||
| 11219376 | FORM 3 SUBMISSION | 2016-08-25 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Marker Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35150/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35150 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35150 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35150 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35150}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Marker Therapeutics, Inc. (id: 35150)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.